Story
GSK's Jemperli Shows Durable Response in Mid-Stage Rectal Cancer Trial
Summary
GSK announced its immunotherapy drug Jemperli achieved its primary endpoint in a Phase II trial, showing a clinically significant rate of sustained remission in patients with a specific subtype of rectal cancer.
GSK (LON:GSK) announced on Monday that its cancer immunotherapy, Jemperli, met its primary endpoint in a mid-stage clinical trial for a specific form of locally advanced rectal cancer. The study demonstrated a clinically meaningful rate of patients who showed no detectable signs of cancer for one year or more following treatment.
Key Trial Findings
The Phase II AZUR-1 trial evaluated Jemperli (dostarlimab) in patients whose rectal cancer tumors are mismatch repair-deficient (dMMR). This genetic characteristic, which prevents the proper repair of DNA damage, is present in an estimated 5% to 10% of the 730,000 global rectal cancer cases diagnosed annually.
According to GSK, the interim data also showed that Jemperli's safety and tolerability profile was consistent with results from previous studies. The company plans to share the full data with global regulators for review.
Significance for Patients and GSK
AdA positive outcome in this patient population is significant because the standard treatment—typically involving chemotherapy, radiation, and surgery—can lead to severe, life-altering consequences, including the need for a colostomy bag and potential infertility. Immunotherapies like Jemperli offer a potential alternative for dMMR tumors, which are known to be highly responsive to this class of drugs.
Jemperli is a cornerstone of GSK's oncology portfolio and a key driver of its long-term growth strategy. The drug, already approved for certain types of endometrial cancer in the U.S. and U.K., generated sales of $1.1 billion in 2025. GSK anticipates Jemperli will be a major contributor to its goal of achieving more than £40 billion ($53.52 billion) in total sales by 2031.
Regulatory and Market Context
The U.S. Food and Drug Administration (FDA) has already granted both Breakthrough Therapy and Fast Track designations to Jemperli for this potential rectal cancer indication, signaling the agency's recognition of its potential to address an unmet medical need. These designations are intended to expedite the development and review of promising new therapies.